Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 29, 2012

GEN Poll Respondents See Euro Crisis Casting a Shadow on U.S. Biopharma Industry

  • More than two-thirds of respondents to a recent GEN poll see the falling Euro having at least some effect on the U.S. biopharma industry. While results are somewhat split, 40.3% of respondents expect the Euro crisis to have “somewhat” of an effect, followed closely by the 34.3% who anticipate “a lot” of impact. Another 20.9% foresee “not much” of an effect, and the remaining 4.5% of respondents were undecided.

    Until now, the result of the Euro’s woes on biopharma can be seen most in the currency’s home continent, where several biopharma giants have attributed sales slumps to the Euro or trends stemming from the Euro’s slide, while Germany has tightened its rules governing pricing of new drugs.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »